incretin


Also found in: Dictionary, Wikipedia.
Related to incretin: Sitagliptin

in·cre·tin

(in-krē'tin),
Generic term for all insulinotropic substances originating in the gastrointestinal tract that are released into the circulation by meals containing glucose. One is glucose-dependent insulinotropic polypeptide, which is released into the circulation from crypt cells in the proximal duodenum and jejunum after meals containing glucose or long-chain fatty acids. Another is proglucagon-derived polypeptide, cleavage product of glucagon, which is further processed into glucagonlike peptide-1 and then to glucagonlike insulinotropic peptide.

incretin

(ĭn-krēt′n)
n.
Any of several gastrointestinal hormones that bring about the release of insulin from the pancreas after carbohydrate ingestion and are essential in maintaining normal levels of glucose in the blood.

in·cre·tin

(in-krē'tin)
Generic term for all insulinotropic substances originating in the gastrointestinal tract that are released into the circulation by meals containing glucose. One is the glucose-dependent insulinotropic polypeptide, which is released into the circulation from crypt cells in the proximal duodenum and jejunum after meals containing glucose or long-chain fatty acids. Another is proglucagon-derived polypeptide, a cleavage product of glucagon, which is further processed into glucagonlike peptide-1 and then to glucagonlike insulinotropic peptide.
Compare: bioregulator

in·cre·tin

(in-krē'tin)
Generic term for all insulinotropic substances originating in the gastrointestinal tract.
Mentioned in ?
References in periodicals archive ?
GIP and GLP-1, the two incretin hormones: Similarities and differences.
Variable anti-edema and anti-granuloma effects of liraglutide and teneligliptin on experimental Wistar albino rat inflammatory models
23) Subsequent to this review, 2 studies of health records from European and North American countries showed no evidence of an associated between incretin drugs and an increased risk of pancreatitis (N=l,532,513) or pancreatic cancer (N=972,384) compared with other glucose-lowering drugs.
Glucagon-Like Peptide-1 Receptor Agonists
Exenatide (Byetta), liraglutide (Victoza) and dulaglutide (Trulicity) are incretin agonists which mimic the actions of the incretin hormones.
Sweet Tooth: Knowledge about type 2 diabetes and the drugs used to treat it can help you better care for patients
They identified patients with type 2 diabetes who received a first prescription of an incretin drug or NIAD from January 2008 through the end of 2013 in Belgium, and through the end of 2012 in Italy.
Rapid deterioration of type 2 diabetes in patients may be marker that they have early pancreatic cancer
Glucagon-like peptide-1 receptor agonists (GLP-1, incretin mimetics) bind and activate the GLP-1 receptor and increase glucose-dependent insulin secretion.
Multipronged approach needed for diabetes
That's where the incretins come into play, he said.
When 1 + 1 = 3: choosing drug combos in type 2 diabetes
Recommendations for Clinicians and People with Diabetes Concerning the Use of Incretin Therapy and Pancreatic Disease, 28 June 2013.
Endocrine and metabolic effects of Glucagon like peptide 1 receptor agonists (GLP1RA)
In response to the review article by Gupta, "Pleiotropic effects of incretins," we conducted a small prospective study to see benefits with injectable incretin liraglutide.
Treatment of obesity: newer perspectives
While long-term prospective cardiovascular outcome studies determining cardiovascular safety and/or protection for many of the incretin agents are still awaited, there is growing evidence that these agents are likely to be more effective than traditional antidiabetic agents in reducing the many long-term and costly complications of T2DM.
Targeting composite treatment of type 2 diabetes in middle-income countries--walking a tightrope between hyperglycaemia and the dangers of hypoglycaemia
The activity is titled 'Best Practice in Type 2 Diabetes: Update on Incretin Therapies in Combination with Insulin'.
New Type 2 Diabetes CME Activity for Healthcare Professionals Launched on epgonline.org
DPP-4 inhibitors are relatively newer and are the only oral agent in the incretin family of therapeutic targets.
Comparative evaluation of combination of metformin and glimepiride with that of metformin and sitagliptin in type 2 diabetes mellitus with respect to glycemic targets
Medications such as exenatide (Byetta) are called incretin mimetics, because they mimic incretins, which are hormones released into the blood when we digest food.
Newer diabetes drugs may be harming your pancreas

Medical browser ?
Full browser ?